Sotorasib (AMG 510), the first KRAS G12C inhibitor, binds to a cysteine residue in the switch II region and prevents activation of KRAS.59 Based on the results of phase 1 and single-arm phase 2 trials, sotorasib was first approved by the Food and Drug Administration (FDA) in 2021 for the treatment of advanced NSCLC in the second line and beyond.60–62 In the phase 3 trial, sotorasib had a significantly longer PFS than docetaxel (5.6 vs. 4.5 months, HR = 0.66, p = .0017), with fewer grade 3 or 4 adverse events.63 A first-line trial of sotorasib (NCT04933695) is currently underway. This evidence concerns the gene KRAS and non-small cell lung carcinoma.